Metsera, Inc.
$70.50
+0.0000%Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -34.7).
Valuation inputs: P/E -34.7, earnings yield N/A, momentum 0.0%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -72.8%, ROIC -54.8%).
Profitability stack: net margin 0.0%, ROE -72.8%, ROIC -54.8%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +36.3%, momentum 0.0%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Metsera, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Metsera, Inc. Fair Value Envelope
No Revenue Data
MTSR has not reported any revenue values in the available annual periods.
Metsera, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
MTSR has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
MTSR has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
MTSR has not reported any net profit margin values in the available annual periods.
Metsera, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Deteriorating cash generation: Both declining FCF and weak conversion rate signal fundamental challenges. Investigate margin pressure, rising costs, or working capital issues.
Metsera, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Metsera, Inc. Street Expectations Map
Wall Street analysts project that MTSR stock may decline over the coming 12 months. The consensus 1-year price target stands at 55.50, with estimates ranging from a low of 54.00 to a high of 57.00.
The consensus 1-year price target stands at 55.50, with estimates ranging from a low of 54.00 to a high of 57.00.
Analyst Consensus Analysis
Upside Potential
Significant downside risk. Stock trading well above analyst consensus suggests elevated valuation concerns and potential correction.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Risk-Reward Profile
Unfavorable risk-reward. Downside risk exceeds upside potential. Consider defensive positioning or alternative opportunities.
Analyst Conviction
Bearish or uncertain outlook. Limited upside or poor consensus suggests challenges ahead or fundamental concerns.
Market Sentiment Insight
Consensus overvaluation: Analysts agree the stock is richly valued with limited upside. Consider booking profits or defensive positioning unless you have contrarian conviction in unrecognized catalysts.
Metsera, Inc. Insider Positioning
During the last 12 months, insiders have sold $21K worth of MTSR shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
193
11.82K
-12K
-$12K
9-12 Months
0
0.00
268
9.65K
-10K
-$10K
Top Buyers
No buying activity
Top Sellers
Fmr Llc
10 Percent Owner, Other: See Remark 1
$21K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $21K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
MTSR has not reported any dividend yield values in the available annual periods.
mtsr Dividend History
Learning Layer
Related Guides
Build conviction on MTSR by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.